Treatment of metastatic colorectal cancer: focus on panitumumab

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)


Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.
Original languageEnglish
Pages (from-to)189 - 198
Number of pages10
JournalCancer Management and Research
Publication statusPublished - 2015

Cite this